Market
Story
FDA Approves Eli Lilly's Zepbound as First and Only Treatment for Sleep Apnea, Reducing Breathing Interruptions by 25
Dec 20, 2024, 09:55 PM
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Zepbound (tirzepatide) as the first and only prescription medication for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This approval, announced on December 20, 2024, allows Zepbound to be used in conjunction with a reduced-calorie diet and increased physical activity. Clinical data indicates that adults using Zepbound experienced at least 25 fewer breathing interruptions per hour, with up to 50% of patients reporting no symptoms after one year of treatment. The approval may also facilitate broader insurance coverage for the medication, which is primarily recognized for its weight-loss benefits.
View original story
Similar markets
Other • 25%
Roche • 25%
Eli Lilly • 25%
Pfizer • 25%
Other • 25%
Imperial Brands • 25%
British American Tobacco • 25%
Altria • 25%
Australia • 25%
European Union • 25%
Other • 25%
United Kingdom • 25%
No • 50%
Yes • 50%
Johnson & Johnson • 25%
Merck • 25%
Pfizer • 25%
Other • 25%
1-2 new partnerships • 25%
3-4 new partnerships • 25%
5 or more new partnerships • 25%
0 new partnerships • 25%
Other • 25%
Pfizer • 25%
GlaxoSmithKline • 25%
Roche • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Johnson & Johnson • 25%
Pfizer • 25%
Other • 25%
More than 15 • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 15 • 25%